Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Dise
Go back to Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Dise| (NYSE: BHVN) | Delayed: 16.03 +0.07 (0.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.96 | 52 Week High | $ | |||
| Open | $16.10 | 52 Week Low | $ | |||
| Day High | $16.44 | P/E | N/A | |||
| Day Low | $15.72 | EPS | $ | |||
| Volume | 423,269 | |||||
